Day 2 - ET (Eastern Time, GMT-05:00)
Day 2 - ET (Eastern Time, GMT-05:00)
Navigate the implications of GFI #256 (2023) on veterinary medicine and animal drug compounding from the bulk drug substance list.
- Viral Jani - Director of Pharmacy Operations, Town & Country Compounding
With the advent – and shortage – of blockbuster GLP-1s over the past 24 months, many Americans are learning about pharmacy compounding for the first time. But much of the media's reporting on shortage drug compounding is inaccurate and misleading. In this session, learn why FDA's shortage drug compounding policies are intentional and essential, what the media gets wrong about compounded GLP-1s in particular, and what compounding professionals should be telling their patients.
- Scott Brunner - Chief Executive Officer, Alliance for Pharmacy Compounding
The FDA has reclassified multiple peptides to the category 2 bulks list due to recently identified safety risks. Join us as we discuss the anticipated implications of these reclassifications in the compounding space
- Gain insights on the challenges with compounded medications not covered by insurance/medicare
- Explore key strategies in liaising with FDA and state boards
- Tenille Davis - Member, Arizona State Board of Pharmacy
- Training and retaining pharmacists and technicians
- Finding qualified talent and following protocol to reduce medication errors
- Understanding certification reports
- Pallavi Badkar - Vice President of Operations and Pharmacist-in-Charge, MedisourceRx
- Scott Shepard - Director of Home Infusion Service, Beth Israel Lahey Health